Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial
about
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisBisphosphonates and other bone agents for breast cancerBisphosphonates in breast cancerHeel ultrasound can assess maintenance of bone mass in women with breast cancer.Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.Medication-induced osteoporosis: screening and treatment strategiesCancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patientsOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineOsteoporosis and aromatase inhibitors: experience and future prospectsPrevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trialCalcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Skeletal manifestations of treatment of breast cancer.A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.Emerging drugs for the management of cancer treatment induced bone loss.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGThe use of bisphosphonates in cancer treatment.Aging and osteoporosis in breast and prostate cancer.The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.A review of osteoporosis management in younger premenopausal women.Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole.Bisphosphonates and other bone agents for breast cancer.Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
P2860
Q21132670-53035047-7B8C-4E09-8922-843E9E3DD11EQ24203656-1FDFB060-1AA7-4CCA-BFC9-97C8D5686CECQ26859326-B980EC52-6592-472F-BA73-FDF9C9FDFDBCQ30383587-0BBE3316-0F33-482A-93E9-CC507C2B7FEBQ30416847-08D08497-FA34-4E03-A3BA-758A9F24E6C7Q33802932-22F50674-6106-4CA6-B247-E42A018026B3Q34389358-669DB9C1-78DB-4D11-8EF9-1FE107DEC150Q34680563-99AC3BFF-7F25-4E2A-AF57-21F933EBB02AQ35012609-3C095506-C029-4B1A-8AEF-0661334300CEQ35076216-3C9ECE2B-AB0A-4FD5-AF85-2C296D926E05Q35095538-2B65E2B6-02A7-4801-9152-CAE329B3FFB1Q35194455-C14BE18C-5EB3-4A1E-9F2A-BF4D9D2C331DQ35583788-924840F3-4F94-4F71-9342-B90FA3976A12Q35750472-7D6E37D5-F5D8-4745-B565-CC344CF8FDF1Q36333474-29941590-E184-4472-8310-F23AE6E8637FQ36616992-45D0D676-D23B-4FFA-AF4A-86E070731425Q37350988-8D1FA984-0A1A-4039-8FB2-41D9A28F8420Q37630298-58BB8F8B-3C00-4639-977F-1A50FF599179Q37653246-392F7329-7DC3-4416-B49A-45B5E31B292AQ37727235-015FDD93-BBC3-4C28-BE39-92920F282F5DQ37742180-702BF1CE-C23C-434C-819A-F011D33C08A1Q37800183-5762F74B-5807-4172-9E8F-D6E930392204Q37872146-F86F9994-B871-44CE-81FB-BBE5DB7019B6Q37944154-C7B7E03D-5535-4DA3-998A-298E593EFC53Q37952851-E3C52B8A-D8F1-4F2A-898B-DA366BBA2728Q38170408-998F9C00-8C50-406E-BD56-82E61BB98939Q38553766-128CCDCB-EC83-4EA4-A272-4DF47FDF274DQ41684442-56C07BFF-0DD4-407B-86AA-35B7E965D5AFQ47693752-75B742E3-FEC2-4236-B529-5AA2EF21AA7EQ49344279-629A12E5-035A-4755-9B02-76395837928FQ53136867-4E78DC26-8DC4-4149-BD08-A131A07EBC2B
P2860
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risedronate prevents bone loss ...... cebo-controlled clinical trial
@en
Risedronate prevents bone loss ...... ebo-controlled clinical trial.
@nl
type
label
Risedronate prevents bone loss ...... cebo-controlled clinical trial
@en
Risedronate prevents bone loss ...... ebo-controlled clinical trial.
@nl
prefLabel
Risedronate prevents bone loss ...... cebo-controlled clinical trial
@en
Risedronate prevents bone loss ...... ebo-controlled clinical trial.
@nl
P2093
P2860
P356
P1476
Risedronate prevents bone loss ...... cebo-controlled clinical trial
@en
P2093
Adam Brufsky
Barry C Lembersky
Karen T Vujevich
Rajib Bhattacharya
Subashan Perera
Susan L Greenspan
Susan M Sereika
Victor G Vogel
P2860
P304
P356
10.1200/JCO.2007.15.2967
P407
P577
2008-04-21T00:00:00Z